Fred Alger Management Inc. Acquires Shares of 3,500 Charles River Laboratories International, Inc. (CRL)

Fred Alger Management Inc. acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,500 shares of the medical research company’s stock, valued at approximately $354,000.

Other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares during the period. Riverhead Capital Management LLC raised its position in Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the period. Cambridge Advisors Inc. purchased a new stake in Charles River Laboratories International in the second quarter valued at $202,000. Advisor Partners LLC purchased a new stake in Charles River Laboratories International in the second quarter valued at $208,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Charles River Laboratories International in the second quarter valued at $217,000. Hedge funds and other institutional investors own 95.38% of the company’s stock.

In related news, insider David Ross Smith sold 2,552 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the transaction, the insider now directly owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George Massaro sold 3,830 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the transaction, the director now directly owns 18,731 shares in the company, valued at $1,888,272.11. The disclosure for this sale can be found here. Insiders sold a total of 22,529 shares of company stock worth $2,278,496 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/10/fred-alger-management-inc-acquires-shares-of-3500-charles-river-laboratories-international-inc-crl.html.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 110.46 on Tuesday. The stock has a 50 day moving average price of $107.04 and a 200-day moving average price of $97.57. The firm has a market capitalization of $5.26 billion, a PE ratio of 29.11 and a beta of 0.96. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $110.82.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period last year, the company posted $1.20 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

CRL has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC restated a “buy” rating and issued a $121.00 target price on shares of Charles River Laboratories International in a research report on Friday, June 30th. BidaskClub downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Robert W. Baird restated a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Finally, Barclays PLC restated a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Six investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $100.50.

About Charles River Laboratories International

Charles River Laboratories In

Other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 202 shares during the period. Riverhead Capital Management LLC raised its position in Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 247 shares during the period. Cambridge Advisors Inc. purchased a new stake in Charles River Laboratories International in the second quarter valued at $202,000. Advisor Partners LLC purchased a new stake in Charles River Laboratories International in the second quarter valued at $208,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Charles River Laboratories International in the second quarter valued at $217,000. Hedge funds and other institutional investors own 95.38% of the company’s stock.

In related news, insider David Ross Smith sold 2,552 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the transaction, the insider now directly owns 11,671 shares of the company’s stock, valued at approximately $783,124.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director George Massaro sold 3,830 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the transaction, the director now directly owns 18,731 shares in the company, valued at $1,888,272.11. The disclosure for this sale can be found here. Insiders sold a total of 22,529 shares of company stock worth $2,278,496 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/10/fred-alger-management-inc-acquires-shares-of-3500-charles-river-laboratories-international-inc-crl.html.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 110.46 on Tuesday. The stock has a 50 day moving average price of $107.04 and a 200-day moving average price of $97.57. The firm has a market capitalization of $5.26 billion, a PE ratio of 29.11 and a beta of 0.96. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $110.82.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period last year, the company posted $1.20 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

CRL has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC restated a “buy” rating and issued a $121.00 target price on shares of Charles River Laboratories International in a research report on Friday, June 30th. BidaskClub downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Robert W. Baird restated a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Finally, Barclays PLC restated a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Six investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $100.50.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply